riccardo masetti

Assistant Professor

University of Bologna
Country flagItaly
ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Explore related searches

Articles (4)

Background Infections are the leading cause of non-relapse mortality in pediatric hematopoietic cell transplant (HCT) recipients. Up to 90% of bacteremias in these patients originate from gut microbiome organisms. However, selection for resistance genes, such as Extended-spectrum β-lactamase (ESBL), in these patient’s gut microbiomes remains poorly understood. Methods Stools were prospectively collected from pediatric HCT recipients at multiple centers (n=133 patients, five centers) on the day of HCT, the day of neutrophil engraftment, and 30 days post-HCT. Bacterial DNA was isolated and sent for shotgun metagenomic sequencing. Antibiotic resistance genes were identified using the MEGARes database. Associations between ESBL gene abundance changes and antibiotic exposure were examined using univariate and Inverse Probability of Treatment Weighting linear regression models with covariate balancing propensity scores. Results Pre-existing gut resistome disruption at the time of HCT showed a stronger correlation with ESBL gene expansion than post-transplant antibiotic exposure. Specifically, patients with greater baseline resistome distance from healthy children showed increased ESBL genes during the neutropenic period. Post-transplant β-lactam exposure (total or ESBL-cleavable) did not correlate with increases in ESBL genes in already-colonized patients. However, aminoglycosides and anaerobic active antibiotics were associated with acquisition of new ESBL organisms during the neutropenic period, while pre-existing microbiome disruption primarily drove selection of resistant bacteria already present. Conclusions These findings indicate that antibiotic stewardship before HCT, in addition to reducing the use of anaerobic active antibiotics during early transplant, may be necessary to prevent ESBL-related infections in pediatric transplant recipients. Lay Summary Infections are the leading cause of death after HCT, and recently the role of the gut microbiome in harboring dangerous bacteria has been highlighted. This study aims to understand multidrug resistant bacteria changes in the gut microbiome early after HCT.

Year:

2026

Juvenile myelomonocytic leukemia (JMML) is a myelodysplastic/myeloproliferative neoplasm of early childhood driven by RAS pathway mutations. Allogeneic hematopoietic stem cell transplantation (HSCT) is the therapy of choice for most patients. However, relapse rate is high, in patients with adverse features, frequently noted in PTPN11 -mutated JMML, or in patients without evidence of graft-versus-host disease (GvHD). Here we set out to understand the mechanisms associated with oncogenic PTPN11 immune escape. Analyzing primary PTPN11 -mutated JMML samples and MxCre;Ptpn11 D61Y/+ mice, we observed elevated expression of immune checkpoint molecules, including ectonucleotidases CD39 and CD73 - key mediators of the adenosine pathway - on monocytic and granulocytic leukemic cells. Stimulation with GM-CSF, a central mediator of JMML pathogenesis, induced ectonucleotidases expression on granulocytes and monocytes. In contrast, MEK inhibition downstream of Ptpn11 D61Y/ + reduced ectonucleotidases expression. Functionally, Ptpn11 D61Y/ + -mutated myeloid cells suppressed activation and proliferation of wild-type (WT) T lymphocytes, an effect recapitulated by adenosine and reversed by pharmacological CD39 inhibition with POM-1. In vivo , POM-1 treatment of MxCre ; Ptpn11 D61Y/+ mice presenting with myeloproliferation reduced spleen size and partially restored immune responsiveness. Moreover, POM-1 induced apoptosis in murine Ptpn11 D61Y/+ myeloid cells, highlighting a dual therapeutic benefit of CD39 inhibition in JMML. Together, these findings suggest that targeting the adenosine pathway may represent an immunomodulatory approach to enhance T cell-mediated control of JMML, particularly in the context of HSCT and relapse prevention.

Year:

2025

Acute lymphoblastic leukemia expressing the gamma delta T-cell receptor (γδ T-ALL) is a poorly understood disease. We studied 200 children with γδ T-ALL from 13 clinical study groups to understand the clinical and genetic features of this disease. We found age and genetic drivers were significantly associated with outcome. γδ T-ALL diagnosed in children under 3 years of age was extremely high-risk and enriched for genetic alterations that result in both LMO2 activation and STAG2 inactivation. Mechanistically, using patient samples and isogenic cell lines, we show that inactivation of STAG2 profoundly perturbs chromatin organization by altering enhancer–promoter looping, resulting in deregulation of gene expression associated with T-cell differentiation. High-throughput drug screening identified a vulnerability in DNA repair pathways arising from STAG2 inactivation, which can be targeted by poly(ADP-ribose) polymerase inhibition. These data provide a diagnostic framework for classification and risk stratification of pediatric γδ T-ALL. Significance: Patients with acute lymphoblastic leukemia expressing the gamma delta T-cell receptor under 3 years old or measurable residual disease ≥1% at end of induction showed dismal outcomes and should be classified as having high-risk disease. The STAG2/LMO2 subtype was enriched in this very young age group. STAG2 inactivation may perturb chromatin conformation and cell differentiation and confer vulnerability to poly(ADP-ribose) polymerase inhibition.

Year:

2024

Objective To evaluate the safety of short-term use of inhaled salbutamol in children under 2 years of age with acute wheezing. Data sources Electronic databases (PubMed, Trip, MEDLINE) and the Cochrane Library were searched for studies published up to October 2022. Study selection The search was restricted to randomised controlled trials published in English regarding the safety of inhaled salbutamol in wheezing children under the age of 2. Data extraction and synthesis The literature search strategy yielded 3532 references. The meta-analysis was conducted in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines. Main outcome(s) and measure(s) The incidence of adverse reactions associated with inhaled salbutamol administration compared with placebo. Results A total of 24 records were included. In 7 studies involving 597 patients, inhaled salbutamol was compared with controls and no statistically significant difference in the incidence of adverse drug reactions was found between the two groups (OR 2.12, 95% CI 0.69 to 6.51; p=0.19). Salbutamol administration via nebulisation was associated with an increased incidence of adverse reactions (OR 6.76, 95% CI 2.01 to 22.71; p=0.002). None of the studies reported severe cardiac side effects that necessitated withdrawal from the study following salbutamol administration. Only one study reported a significant non-cardiac side effect (severe tremulousness) that necessitated withdrawal from therapy. Conclusions Inhaled salbutamol can be safely used in children under 2 years of age with acute wheeze with the administration via a metered-dose inhaler being potentially safer than a nebulised formulation. Neither of the formulations was associated with severe adverse effects.

Year:

2024

Collaborators (37)

Shondra Pruett-Miller

Associate Member

St. Jude Children's Research Hospital

UNITED STATES
View details

Mariko Eguchi

Profesor

Ehime University Graduate School of Medicine

JAPAN
View details

Chi Kong Li

Professor

The Chinese University of Hong Kong (CUHK)

HONG KONG
View details

Martin Schrappe

-

GERMANY
View details

Kjeld Schmiegelow

-

DENMARK
View details

Hanne Vibeke Hansen Marquart

Chief Physician; MD, PhD, Clinical Associate Professor

Copenhagen University Hospital

DENMARK
View details

Allen Eng Juh Yeoh

National University of Singapore (NUS)

SINGAPORE
View details

Atsushi Manabe

Professor

Hokkaido University

JAPAN
View details

Gabriele Escherich

-

GERMANY
View details

Valentino Conter

-

ITALY
View details

John Choi

The University of Alabama

UNITED STATES
View details

Franco Locatelli

Full Professor of Pediatrics

Catholic University of the Sacred Heart

ITALY
View details

Elisa Margolis

Associate Professor

University of Utah

UNITED STATES
View details

Steven Kornblau

Professor

The University of Texas MD Anderson Cancer Center

UNITED STATES
View details

Junko Takita

教授 / Professor

Kyoto University

JAPAN
View details

Szymon Skoczen

Associated Professor

Uniwersytet Jagiellonski Collegium Medicum

POLAND
View details

Kathryn Roberts

St. Jude Children's Research Hospital

UNITED STATES
View details

David Teachey

Professor

Children's Hospital of Philadelphia

UNITED STATES
View details

Daisuke Tomizawa

Head

National Center For Child Health and Development

JAPAN
View details

Miriam Erlacher

Medical Director, Professor of Pediatrics

University Hospital Ulm

GERMANY
View details

Cheng Cheng

Professor

St Jude Grade School of Biomedical Sciences

UNITED STATES
View details

Janet Englund

Professor

-

UNITED STATES
View details

Motohiro Kato

-

JAPAN
View details

Takao Deguchi

Head of Division

National Center For Child Health and Development

JAPAN
View details

Robert Zeiser

Director Div. of Tumor immunology/Professor

University Medical Center Freiburg

GERMANY
View details

Ching-Hon Pui

Fahad Nasser Al-Rashid Chair of Leukemia Research

St. Jude Children's Research Hospital

UNITED STATES
View details

Andrew Moore

Associate Professor

University of Queensland

AUSTRALIA
View details

Ilaria Iacobucci

Principal Scientist

St. Jude Children's Research Hospital

UNITED STATES
View details

Joshua Wolf

St. Jude Children's Research Hospital

UNITED STATES
View details

Edoardo Muratore

University of Bologna

ITALY
View details

Masatoshi Takagi

Tokyo Medical and Dental University

JAPAN
View details

Zhaohui Gu

Assistant Professor

Beckman Research Institute, City of Hope

UNITED STATES
View details

Paul G Thomas

Professor

Fred Hutch Cancer Center

UNITED STATES
View details

Andishe Attarbaschi

Medical University of Vienna

AUSTRIA
View details

Charles Mullighan

Senior Deputy Director, St. Jude Children's Research Hospital Comprehensive Cancer Center

St. Jude Children's Research Hospital

UNITED STATES
View details

Rishi Kotecha

Professor

Telethon Kids Institute

AUSTRALIA
View details

Eileen Klein

Professor

University of Washington

UNITED STATES
View details